公开(公告)号：US20250099605A1

公开(公告)日：2025-03-27

申请号：US18805405

申请日：2024-08-14

Applicant: Gilead Sciences, Inc. ,  MSD International GmbH ,  MSD International Business GmbH

Inventor： Sabeen Fatima MEKAN ,  Bilal PIPERDI ,  Amy Elizabeth OTTO

IPC: A61K47/68 ,  A61K39/395 ,  A61P35/00

Abstract: The present disclosure relates to methods of treating a treatment naïve metastatic NSCLC in a patient, comprising administering sacituzumab govitecan (SG) and an anti-PD-1 antibody or antigen binding fragment thereof.

公开(公告)号：US20240245792A1

公开(公告)日：2024-07-25

申请号：US18525282

申请日：2023-11-30

Applicant: Synthorx, Inc. ,  MSD INTERNATIONAL GMBH ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Giovanni Abbadessa ,  Carolina E. Caffaro ,  Brigitte Demers ,  Joseph Leveque ,  Wan-Ju Meng ,  Marcos Milla ,  Jerod Ptacin

IPC: A61K47/64 ,  A61K39/00 ,  A61P35/04 ,  C07K16/22 ,  C07K16/28

CPC classification number: A61K47/642 ,  A61P35/04 ,  C07K16/22 ,  C07K16/2818 ,  C07K16/2863 ,  A61K2039/507

Abstract: Disclosed herein are methods for treating head and neck squamous cell carcinoma (HNSCC) in a subject in need thereof, comprising administering IL-2 conjugates in combination with one or more additional agents.

公开(公告)号：US20240409653A1

公开(公告)日：2024-12-12

申请号：US18698354

申请日：2022-10-05

Applicant: GENMAB A/S ,  BIONTECH SE ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Alexander MUIK ,  Kristina NÜRMBERGER ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20230346789A1

公开(公告)日：2023-11-02

申请号：US18193958

申请日：2023-03-31

Applicant: MSD International GmbH ,  MSD International Business GmbH ,  Servier Pharmaceuticals LLC.

Inventor： Patrick WEN ,  Tim CLOUGHESY ,  Islam HASSAN

IPC: A61K31/53 ,  A61K39/395

CPC classification number: A61K31/53 ,  A61K39/3955

Abstract: Provided are methods for treating enhancing brain tumors in patients in need thereof using a combination of an inhibitor of mutant IDH1/2 enzyme and an anti PD-1 agent.

公开(公告)号：US20240216470A1

公开(公告)日：2024-07-04

申请号：US18440775

申请日：2024-02-13

Applicant: Werewolf Therapeutics, Inc. ,  MSD International Business GmbH

Inventor： William WINSTON ,  Daniel HICKLIN ,  Jose Andres SALMERON-GARCIA ,  Cynthia SEIDEL-DUGAN ,  Heather BRODKIN ,  Randi ISAACS

IPC: A61K38/20 ,  A61K31/337 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/513 ,  A61K31/519 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K38/2013 ,  A61K31/337 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/513 ,  A61K31/519 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  A61K2039/545

Abstract: This disclosure relates to methods and compositions for treating cancer using a combination therapy comprising an inducible IL-2 prodrug in combination with pembrolizumab.